Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
In Brief

AACR publishes annual impact report

The American Association for Cancer Research presented its 2023 Annual Impact Report. 
March 08, 2024
Vol.50 No.10
In Brief

Medical College of Wisconsin constructing cancer research building

The Medical College of Wisconsin faculty, researchers, staff, and students were invited to sign a construction beam that will soon become a permanent fixture of the new MCW Cancer Research Building.
March 08, 2024
Vol.50 No.10
First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.
February 23, 2024
Vol.50 No.08
By Matthew Bin Han Ong
Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research
Conversation with The Cancer Letter

Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research

Feb. 16, 2024, is a landmark date in the history of immuno-oncology.
February 23, 2024
Vol.50 No.08
By Matthew Bin Han Ong
In Brief

James Allan named chair of Foundation for Biomedical Research board of directors

James S. Allan was named chair of the Foundation for Biomedical Research board of directors.
February 16, 2024
Vol.50 No.07
Impact factor mania and publish-or-perish may have contributed to Dana-Farber retractions, experts say

Impact factor mania and publish-or-perish may have contributed to Dana-Farber retractions, experts say
Learning from past errors (and misconduct) in cancer research

More than a decade ago, Glenn Begley and Lee Ellis published a paper with astounding findings: of 53 “landmark” studies, only six, or 11%, were reproducible, even with the same reagents and the same protocols—and even, sometimes, in the same laboratory—as the original study.
February 02, 2024
Vol.50 No.05
By Jacquelyn Cobb
Dana-Farber to retract six papers, correct 31, over “image discrepancies” in papers co-authored by top leaders

Dana-Farber to retract six papers, correct 31, over “image discrepancies” in papers co-authored by top leaders

Over 50 research papers that list top leaders of Dana-Farber Cancer Institute among authors are implicated in an investigation of allegations of data manipulation. 
January 26, 2024
Vol.50 No.04
By Jacquelyn Cobb
In Brief

AACR names 2024 fellows of AACR Academy

The American Association for Cancer Research has elected the 2023 class of fellows of the AACR Academy.
January 19, 2024
Vol.50 No.03
In Brief

SU2C announces three research teams to study gastroesophageal cancer

Stand Up To Cancer has announced three Research Teams focused on bringing new therapies to clinical trials for the treatment of gastroesophageal cancer. 
November 17, 2023
Vol.49 No.43
High-risk investments by ARPA-H aim to catalyze a new era in cancer research

High-risk investments by ARPA-H aim to catalyze a new era in cancer research

The Advanced Research Projects Agency for Health is setting up a network of partners that would enable the federal government to fund and roll out new initiatives nationwide.
October 27, 2023
Vol.49 No.40
By Matthew Bin Han Ong

Posts navigation

Previous1…131415Next

Trending Stories

  • Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
    Brian Druker returns to executive role as president of the new Knight Cancer Group
  • Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
  • ACOG says it will no longer accept federal funding
  • Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
  • The Med Student’s Memo – Research Concerns
  • FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2025 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation
Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account